Stuart
Executive Summary
Richard Davies to VP-clinical & medical affairs.
You may also be interested in...
Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.
BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A
Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: